Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats

Akbar Ahmad, Tiziana Genovese, Daniela Impellizzeri, Rosalia Crupi, Enrico Velardi, Angela Marino, Emanuela Esposito, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Stroke is the third leading cause of death and the leading cause of long-term disability in adults. Current therapeutic strategies for stroke, including thrombolytic drugs, such as tissue plasminogen activator offer great promise for the treatment, but complimentary neuroprotective treatments are likely to provide a better outcome. To counteract the ischemic brain injury in mice, a new therapeutic approach has been employed by using palmitoylethanolamide (PEA). PEA is one of the members of N-acyl-ethanolamine family maintain not only redox balance but also inhibit the mechanisms of secondary injury on ischemic brain injury. Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level (assayed by Bax and Bcl-2) further support the efficacy of PEA therapy. We demonstrated that PEA treatment blocked infiltration of astrocytes and restored MCAo-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, growth factors (BDNF and GDNF) and GFAP. PEA also inhibited the MCAo-mediated increased expression of pJNK, NF-κB, and degradation of IκB-α. PEA-treated injured animals improved neurobehavioral functions as evaluated by motor deficits. Based on these findings we propose that PEA would be useful in lowering the risk of damage or improving function in ischemia-reperfusion brain injury-related disorders.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalBrain Research
Volume1477
DOIs
StatePublished - Oct 5 2012
Externally publishedYes

Fingerprint

Middle Cerebral Artery Infarction
Brain Injuries
Therapeutics
Stroke
Chymases
Glial Cell Line-Derived Neurotrophic Factor
palmidrol
Tryptases
Ethanolamine
Fibrinolytic Agents
Brain-Derived Neurotrophic Factor
Brain Edema
Tissue Plasminogen Activator
Reperfusion Injury
Astrocytes
Oxidation-Reduction
Cause of Death
Histology
Apoptosis
Staining and Labeling

Keywords

  • Apoptosis
  • Cerebral ischemia
  • Inflammation
  • Neuronal death
  • Nitrotyrosine
  • NO

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. / Ahmad, Akbar; Genovese, Tiziana; Impellizzeri, Daniela; Crupi, Rosalia; Velardi, Enrico; Marino, Angela; Esposito, Emanuela; Cuzzocrea, Salvatore.

In: Brain Research, Vol. 1477, 05.10.2012, p. 45-58.

Research output: Contribution to journalArticle

Ahmad, A, Genovese, T, Impellizzeri, D, Crupi, R, Velardi, E, Marino, A, Esposito, E & Cuzzocrea, S 2012, 'Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats', Brain Research, vol. 1477, pp. 45-58. https://doi.org/10.1016/j.brainres.2012.08.006
Ahmad, Akbar ; Genovese, Tiziana ; Impellizzeri, Daniela ; Crupi, Rosalia ; Velardi, Enrico ; Marino, Angela ; Esposito, Emanuela ; Cuzzocrea, Salvatore. / Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. In: Brain Research. 2012 ; Vol. 1477. pp. 45-58.
@article{7899419f930e4be2bee66e7be068d667,
title = "Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats",
abstract = "Stroke is the third leading cause of death and the leading cause of long-term disability in adults. Current therapeutic strategies for stroke, including thrombolytic drugs, such as tissue plasminogen activator offer great promise for the treatment, but complimentary neuroprotective treatments are likely to provide a better outcome. To counteract the ischemic brain injury in mice, a new therapeutic approach has been employed by using palmitoylethanolamide (PEA). PEA is one of the members of N-acyl-ethanolamine family maintain not only redox balance but also inhibit the mechanisms of secondary injury on ischemic brain injury. Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level (assayed by Bax and Bcl-2) further support the efficacy of PEA therapy. We demonstrated that PEA treatment blocked infiltration of astrocytes and restored MCAo-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, growth factors (BDNF and GDNF) and GFAP. PEA also inhibited the MCAo-mediated increased expression of pJNK, NF-κB, and degradation of IκB-α. PEA-treated injured animals improved neurobehavioral functions as evaluated by motor deficits. Based on these findings we propose that PEA would be useful in lowering the risk of damage or improving function in ischemia-reperfusion brain injury-related disorders.",
keywords = "Apoptosis, Cerebral ischemia, Inflammation, Neuronal death, Nitrotyrosine, NO",
author = "Akbar Ahmad and Tiziana Genovese and Daniela Impellizzeri and Rosalia Crupi and Enrico Velardi and Angela Marino and Emanuela Esposito and Salvatore Cuzzocrea",
year = "2012",
month = "10",
day = "5",
doi = "10.1016/j.brainres.2012.08.006",
language = "English (US)",
volume = "1477",
pages = "45--58",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats

AU - Ahmad, Akbar

AU - Genovese, Tiziana

AU - Impellizzeri, Daniela

AU - Crupi, Rosalia

AU - Velardi, Enrico

AU - Marino, Angela

AU - Esposito, Emanuela

AU - Cuzzocrea, Salvatore

PY - 2012/10/5

Y1 - 2012/10/5

N2 - Stroke is the third leading cause of death and the leading cause of long-term disability in adults. Current therapeutic strategies for stroke, including thrombolytic drugs, such as tissue plasminogen activator offer great promise for the treatment, but complimentary neuroprotective treatments are likely to provide a better outcome. To counteract the ischemic brain injury in mice, a new therapeutic approach has been employed by using palmitoylethanolamide (PEA). PEA is one of the members of N-acyl-ethanolamine family maintain not only redox balance but also inhibit the mechanisms of secondary injury on ischemic brain injury. Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level (assayed by Bax and Bcl-2) further support the efficacy of PEA therapy. We demonstrated that PEA treatment blocked infiltration of astrocytes and restored MCAo-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, growth factors (BDNF and GDNF) and GFAP. PEA also inhibited the MCAo-mediated increased expression of pJNK, NF-κB, and degradation of IκB-α. PEA-treated injured animals improved neurobehavioral functions as evaluated by motor deficits. Based on these findings we propose that PEA would be useful in lowering the risk of damage or improving function in ischemia-reperfusion brain injury-related disorders.

AB - Stroke is the third leading cause of death and the leading cause of long-term disability in adults. Current therapeutic strategies for stroke, including thrombolytic drugs, such as tissue plasminogen activator offer great promise for the treatment, but complimentary neuroprotective treatments are likely to provide a better outcome. To counteract the ischemic brain injury in mice, a new therapeutic approach has been employed by using palmitoylethanolamide (PEA). PEA is one of the members of N-acyl-ethanolamine family maintain not only redox balance but also inhibit the mechanisms of secondary injury on ischemic brain injury. Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level (assayed by Bax and Bcl-2) further support the efficacy of PEA therapy. We demonstrated that PEA treatment blocked infiltration of astrocytes and restored MCAo-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, growth factors (BDNF and GDNF) and GFAP. PEA also inhibited the MCAo-mediated increased expression of pJNK, NF-κB, and degradation of IκB-α. PEA-treated injured animals improved neurobehavioral functions as evaluated by motor deficits. Based on these findings we propose that PEA would be useful in lowering the risk of damage or improving function in ischemia-reperfusion brain injury-related disorders.

KW - Apoptosis

KW - Cerebral ischemia

KW - Inflammation

KW - Neuronal death

KW - Nitrotyrosine

KW - NO

UR - http://www.scopus.com/inward/record.url?scp=84866385818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866385818&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2012.08.006

DO - 10.1016/j.brainres.2012.08.006

M3 - Article

VL - 1477

SP - 45

EP - 58

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -